The “Cell Cycle” pathway is also enriched by inhibiting Aurora kinase-B and Aurora kinase-A and downregulating TUBB, TUBB4B, MYC and TUBA1A and upregulating CCND3. Another important enriched pathway is the “Acute myeloid leukaemia” pathway by inhibiting RAF1 and down-regulating MYC. We can hence conclude that genes targeted by fenbendazole according to CMap data has biological relevance to leukaemia according to literature. Here, AURKA is linked to leukemia.